EDINBURGH, Scotland, March 21,
2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC
BioPharm" or the "Company"), (NASDAQ: TCBP) a clinical-stage
biotechnology company developing platform allogeneic gamma-delta T
cell therapies for cancer and other indications, today announced
that on March 20, 2025, it received
notice that the Nasdaq Hearings Panel had determined to delist
the Company's securities from The Nasdaq Stock Market
LLC ("Nasdaq") due to the Company's failure to comply with
Rule 5550(a)(2) of Nasdaq's Listing Rules. The Rule requires listed
securities to maintain a minimum bid price of $1.00 per share. Management is currently
working on an appeal with Nasdaq.
The Company's securities will be suspended for trading on Nasdaq
effective at the opening of trading on Monday, March 24, 2025.
The Company expects its American Depositary Shares to be eligible
to trade on the OTC Markets effective with the opening of trading
on Monday, March 24, 2025. This delisting and transition to
the OTC Markets will not change the Company's obligation to file
annual reports and certain other reports with
the SEC under the applicable federal securities laws. The
Company cautions the reader to read this press release in its
entirety and refer to the Company's press releases and reports
filed with the SEC, including the risks and uncertainties
discussed therein, before making any investment decision.
TC BioPharm remains fully committed to advancing its innovative
research, clinical trials, and therapeutic development
initiatives.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company
focused on discovering, developing, and commercializing gamma-delta
T-cell therapies for cancer treatment with human efficacy data in
acute myeloid leukemia. Gamma-delta T cells are naturally occurring
immune cells that embody properties of both the innate and adaptive
immune systems and can intrinsically differentiate between healthy
and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell
therapies and the first company to conduct phase II/pivotal
clinical studies in oncology. The Company is conducting two
investigator-initiated clinical trials for its unmodified
gamma-delta T cell product line - Phase 2b/3 pivotal trial in the treatment of acute
myeloid leukemia using the Company's proprietary allogeneic CryoTC
technology to provide frozen product to clinics worldwide.
Forward-Looking Statements for TC BioPharm
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this Current Report on Form 8-K
that do not relate to matters of historical fact should be
considered forward-looking statements, including without limitation
statements regarding the Company's intent or ability to affect any
budget savings or execute on any M&A or capital raising
strategy. These statements are based on management's current
assumptions and are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors
that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. For other important factors that could
cause actual results to differ materially from the forward-looking
statements in this Current Report on Form 8-K, please see the risks
and uncertainties identified under the heading "Risk Factors" in
our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed
with the SEC, all of which is available on the Company's Investor
Relations website at www.tcbiopharm.com and on the SEC website at
www.sec.gov. All forward-looking statements reflect the Company's
beliefs and assumptions only as of the date of this Current Report
on Form 8-K. The Company undertakes no obligation to update
forward-looking statements to reflect future events or
circumstances.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tcbp-announces-transition-from-nasdaq-to-otc-markets-302408102.html
SOURCE TC BioPharm